The Department of Defense (DOD) awarded Ology Bioservices and INOVIO a contract valued at $11.9 million to partner to rapidly manufacture a COVID-19 DNA vaccine. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.

In April 2015, INOVIO received a grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop a DNA vaccine against Ebola, a therapeutic DNA-encoded monoclonal antibody product (dMAb™) to treat Ebola infection, and a conventional monoclonal antibody to treat Ebola. In March 2019, INOVIO announced that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data published in The Journal of Infectious Diseases, demonstrated that intradermal (skin) administration with INOVIO’s CELLECTRA® delivery device resulted in 100% of evaluable subjects generating antigen-specific antibody responses that persisted for more than one year in most subjects and generated T cell responses equivalent to or better than the group that received intramuscular delivery.

INOVIO and its collaborators received a seven-year, $25 million grant from National Institutes of Health’s National Institute of Allergy and Infectious Diseases NIH/NIAID) to develop a single or combination therapy using PENNVAX®– GP, with the goal of attaining long-term HIV remission in the absence of antiviral drugs. PENNVAX®-GP is a developmental vaccine intended to prevent and treat HIV strains present in Africa, Asia, Europe, and North America. This comprehensive targeting gives PENNVAX®-GP the potential to provide global coverage against HIV-1 subtypes.

In June 2019, INOVIO received funding from the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) to further the development of its commercial intradermal delivery device. DTRA’s Medical CBRN Defense Consortium provided funding to support the development of an intradermal device branded as CELLECTRA® 3PSP to be used in the administration of INOVIO’s vaccines and therapies which include DTRA developed products. In addition to the development of the CELLECTRA 3PSP device, the award funds the investigation of DNA vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the new device.

INOVIO and GeneOne Life Science, are collaborating with the Walter Reed Army Institute of Research (WRAIR) in Maryland, to conduct clinical trials for a Middle East Respiratory Syndrome (MERS) DNA vaccine in development.